lafutidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H2-receptor antagonists, cimetidine derivatives	1537	206449-93-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

FRG 8813
FRG-8813
lafutidine
laflutidine
protecadin

histamine H(2)-receptor antagonist used as an antiulcer drug

Molecular weight: 431.55
Formula: C22H29N3O4S
CLOGP: 1.80
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 84.67
ALOGS: -3.25
ROTB: 11

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IGF1R,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ZAP70	52
kinase-selectivity-class	AXL,BRAF,CDK9,DDR1,EPHB4,GRK2,MAP2K6,MAPK7,SIK2,STK33,TEK	11
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	60.18	39.12	26	636	136943	90490842
Interstitial lung disease	45.32	39.12	18	644	76387	90551398

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	36.22	27.72	25	717	138556	42482037
Interstitial lung disease	32.60	27.72	19	723	78443	42542150

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	91.71	30.08	51	1564	230392	110357292
Interstitial lung disease	75.67	30.08	38	1577	139296	110448388
Neutrophil count decreased	40.54	30.08	24	1591	120917	110466767
White blood cell count decreased	34.99	30.08	28	1587	229362	110358322

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BA08	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006635	Histamine H2 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018494	Histamine Agents
CHEBI has role	CHEBI:49201	anti-ulcer drug

Related Drugs by ATC class:

A02BA H2-receptor antagonists 6 drugs

cimetidine famotidine niperotidine nizatidine ranitidine roxatidine acetate

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gastro-esophageal reflux disease with esophagitis	indication	266433003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.06	acidic
pKa2	7.57	Basic
pKa3	2.04	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01131	KEGG_DRUG
C0172827	UMLSCUI
CHEBI:31759	CHEBI
CHEMBL1742461	ChEMBL_ID
DB12770	DRUGBANK_ID
C076948	MESH_SUPPLEMENTAL_RECORD_UI
5282136	PUBCHEM_CID
7173	INN_ID
49S4O7ADLC	UNII
49S4O7ADLC	INXIGHT DRUGS

Pharmaceutical products:

None